(CercleFinance.com) – The Nicox ophthalmology laboratory announces that the first of two phase 3 studies on its NCX 470 in glaucoma, the Mont Blanc study, has reached the efficacy required for approval in the United States, while being well tolerated.
The once-daily administered product indeed achieved its primary efficacy endpoint by demonstrating non-inferiority to latanoprost with an intraocular pressure (IOP) lowering effect of 8.0 to 9.7 mmHg compared to basic value.
It was statistically superior to baseline at four of the six endpoints, and numerically superior at all six points, but the secondary endpoint of efficacy, statistical superiority to latanoprost, n was not reached.